10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||
| ||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ABBVIE INC. | |||
Ticker: ABBV Fiscal Year: 2015 | |||
Consolidated Statements of Cash Flows | |||
Period Ending Dec 31, 2015 10-K (Filed: Feb 19, 2016) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2015 | Dec 31, 2014 | Dec 31, 2013 | |
| Cash flows from operating activities | |||
| Net earnings | $ 5,144 | 1,774 | 4,128 |
| Adjustments to reconcile net earnings to net cash from operating activities: | |||
| Depreciation | 417 | 383 | 388 |
| Amortization of intangible assets | 419 | 403 | 509 |
| Stock-based compensation | 282 | 241 | 212 |
| Upfront costs and milestones related to collaborations | 280 | 1,102 | 338 |
| Other, net | 489 | 434 | 34 |
| Changes in operating assets and liabilities, net of acquisitions: | |||
| Accounts and other receivables | (1,076) | (172) | 681 |
| Inventories | (434) | (203) | (56) |
| Prepaid expenses and other assets | 511 | (220) | 459 |
| Accounts payable and other liabilities | 1,503 | (193) | (426) |
| Cash flows from operating activities | 7,535 [1] | 3,549 | 6,267 |
| Cash flows from investing activities | |||
| Acquisitions of Pharmacyclics, Inc., net of cash acquired | (11,488) | ||
| Other acquisitions and investments | (964) | (622) | (405) |
| Acquisitions of property and equipment | (532) | (612) | (491) |
| Purchases of investment securities | (851) | (1,169) | (930) |
| Sales and maturities of investment securities | 880 | 1,477 | 2,705 |
| Other | 19 | ||
| Cash flows from investing activities | (12,936) | (926) | 879 |
| Cash flows from financing activities | |||
| Net change in short-term borrowings | (19) | 12 | (601) |
| Proceeds from issuance of long-term debt | 20,660 | ||
| Repayments of long-term debt and capital leases | (4,018) | (17) | |
| Debt issuance cost | (182) | (141) | |
| Dividends paid | (3,294) | (2,661) | (2,555) |
| Purchases of treasury stock | (7,567) | (652) | (320) |
| Proceeds from the exercise of stock options | 142 | 225 | 347 |
| Net transactions with Abbott Laboratories, excluding non-cash items | (247) | ||
| Other, net | 30 | (59) | (66) |
| Cash flows from financing activities | 5,752 | (3,293) | (3,442) |
| Effect of exchange rate changes on cash and equivalents | (300) | (577) | (10) |
| Net increase (decrease) in cash and equivalents | 51 | (1,247) | 3,694 |
| Cash and equivalents, beginning of period | 8,348 | 9,595 | |
| Cash and equivalents, end of period | 8,399 | 8,348 | 9,595 |
| Supplemental Schedule of Non-Cash Investing and Financing Activities | |||
| Issuance of common stock associated with the acquisition of Pharmacyclics, Inc. | 8,405 | ||
| Other supplemental information | |||
| Interest paid, net of portion capitalized | 536 | 419 | 283 |
| Income taxes paid | 1,108 | 498 | 1,305 |
| [1] Cash flows from operating activities included the impact of transaction and financing-related and other costs incurred in connection with the terminated proposed combination with Shire plc. Refer to Note 5 for additional information. | |||
| External Links | |
| ABBVIE INC. (ABBV) Fiscal Year 2015 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |